New York City
About Dante LabsDante Labs is an international NGS-based biotech company with offices in Europe and the United States. Please use the form below to inquire about our tests, research grant opportunities and potential partnerships.
CEO: Andrea Riposati
Please click here for Dante Labs' products.
18 articles with Dante Labs
Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team
Dante Labs today announced the appointment of Rachel Haverfield to the company’s leadership as General Counsel to drive the growth and scale of the business and opportunity.
Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director
Dante Labs today announced the appointments of Andre Nel, Dalila Rahmani, Laura D’Angelo and Omar Elbakshish to the company’s management team, expanding its global leadership to help scale the growing business.
9/3/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Dante Labs Announces Appointment of Sandra Close to its Board of Directors to Support Strategic Initiatives in Diagnostics
Dante Labs announced today the appointment of Sandra Close, Ph.D., as a member of its Board of Directors.
Dante Labs Announces Appointment of Mark Van Oene to its Board of Directors to Support Operational Approach and Commercial Strategy
Dante Labs announced today the appointment of Mark Van Oene as a member of its Board of Directors.
Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States
Dante Labs announced today the appointment of Mark Morgan as a board member.
Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy
Dante Labs, a global leader in genomics and precision medicine, announced the appointment of Bob Ragusa as a board member.
Dante Labs commits to ending Rare Disease Odysseys globally through Stripe2be: a patient-centric whole genome based solution tailored for rare disease patients
Dante Labs announced the launch of Stripe2be, a platform and business unit fully dedicated to rare disease patients, offering personalized, AI-driven reports based on Whole Genome Sequencing and leveraging Dante Labs’ CE-IVD, ISO13485 certified Immensa Genomic Interpretation Software.
Dante Labs, a leading genomics and diagnostics company, announced the acquisition of Cambridge Cancer Genomics, a groundbreaking Y-Combinator company & leader in machine learning for clinical oncology, to create a single platform with unparalleled capabilities in genomics and oncology data analysis.
Dante Labs announces appointments of Paul Jones, Simon Partridge and Christian Bourne to turbo-charge global population genomics programmes
Paul Jones, Simon Partridge and Christian Bourne, previously from Illumina and Genomics England, have joined Dante Labs in its new Cambridge, UK office to spearhead its ground-breaking global population genomics offer
Dante Labs achieves ISO 13485 certification for its Genomic Interpretation Software Immensa, leveraging an 18 month long clinical validation study of 500,000 samples
Dante Labs, a world leader in genomic sequencing and data analysis, announced that it received ISO 13485:2016 certification for its Immensa Genomic Interpretation Software as a medical device.
Dante Labs £30M investment in Cambridge will support global COVID-19 sequencing surveillance program
Dante Labs has already analysed two million and a half COVID-19 RT-PCR tests and sequenced more than 30,000 human whole genomes thanks to its Immensa™ Genome Platform
Dante Labs, Cambridge Cancer Genomics and Nonacus Collaborate to Provide Precision Oncology at Scale
Partnership aims to deliver the most comprehensive, cost effective and high throughput cancer sequencing and interpretation service in Europe, to enable improved cancer patient management, treatment, and monitoring
Rare Disease Patients will receive Whole Genome Sequencing with Rare Disease Reports for $299 (€289). Patient Groups are encouraged to contact Dante Labs to develop personalized reports for their members (ex. Epilepsy Report for Epilepsy Groups).
Dante Labs Launches Whole GenomeH, the First Human Whole Genome Sequencing Test With Hybrid Genome Assembly
Dante Labs announced its newest, in-house, sequencing test: GenomeH – the first hybrid whole genome sequencing test to leverage hybrid genome assembly and combine short and long reads sequencing in a single application, for superior coverage, accuracy and precision of the genome.
Dante Labs introduced Whole Genome and WholeGenomeZ™ Sequencing and reports with a best-in-class two week turnaround time thanks to its brand new European sequencing centre
Dante Labs to Offer Consumer Access to Whole Genome Sequencing for Disease and Health Information Using Illumina Sequencers
Dante Labs announced that it has begun installing Illumina next generation sequencing technology at its new European headquarters in Italy to make whole genome sequencing and whole exome sequencing available and accessible to individuals around the world through its global direct-to-consumer genomics platform.
International biotech company Dante Labs announced today the offer of whole genome sequencing (WGS) with interpretation for only $229 (€199).